FK-506-13C-d2
FK-506-13C-d2 物理性質
- 貯蔵温度 :
- -70°C
- 溶解性:
- Chloroform: Slightly Soluble,Methanol: Slightly Soluble
- 外見 :
- A solid
安全性情報
- リスクと安全性に関する声明
- 危険有害性情報のコード(GHS)
絵表示(GHS) |
|
注意喚起語 |
|
危険有害性情報 |
コード |
危険有害性情報 |
危険有害性クラス |
区分 |
注意喚起語 |
シンボル |
P コード |
H301 |
飲み込むと有毒 |
急性毒性、経口 |
3 |
危険 |
|
P264, P270, P301+P310, P321, P330,P405, P501 |
|
注意書き |
P264 |
取扱い後は皮膚をよく洗うこと。 |
P264 |
取扱い後は手や顔をよく洗うこと。 |
P270 |
この製品を使用する時に、飲食または喫煙をしないこ と。 |
P301+P310 |
飲み込んだ場合:直ちに医師に連絡すること。 |
P321 |
特別な処置が必要である(このラベルの... を見よ)。 |
P330 |
口をすすぐこと。 |
P405 |
施錠して保管すること。 |
P501 |
内容物/容器を...に廃棄すること。 |
|
FK-506-13C-d2 価格
もっと(5)
メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
富士フイルム和光純薬株式会社(wako)
|
W01TRCF370002 |
FK-506-13C,D2 (Major) (Tacrolimus)(>85%) |
1356841-89-8 |
0.5mg |
¥180600 |
2024-03-01 |
購入 |
富士フイルム和光純薬株式会社(wako)
|
W01TRCF370002 |
FK-506-13C,D2 (Major) (Tacrolimus)(>85%) |
1356841-89-8 |
2.5mg |
¥802800 |
2024-03-01 |
購入 |
富士フイルム和光純薬株式会社(wako)
|
W01TRCF370002 |
FK-506-13C,D2 (Major) (Tacrolimus)(>85%) |
1356841-89-8 |
5mg |
¥687500 |
2018-12-26 |
購入 |
富士フイルム和光純薬株式会社(wako)
|
W01TRCF370002 |
FK-506-13C,D2 (Major) (Tacrolimus)(>85%) |
1356841-89-8 |
1mg |
¥162500 |
2018-12-26 |
購入 |
Sigma-Aldrich Japan
|
T-066 |
100?μg/mL in acetonitrile, certified reference material, ampule of 1?mL
Tacrolimus-13C,D2 solution 100?μg/mL in acetonitrile, certified reference material, ampule of 1?mL |
1356841-89-8 |
1ml |
¥179700 |
2018-12-25 |
購入 |
FK-506-13C-d2 化学特性,用途語,生産方法
説明
FK-506-
13C-d
2 contains two deuterium atoms located on the carbon-13 bond. It is intended for use as an internal standard for the quantification of FK-506 by GC- or LC-MS. FK-506 is a potent, clinically-useful immunosuppressant in the same molecular class as cyclosporin A and rapamycin. Its mechanism of action involves the formation of a high affinity complex (K
i = 0.2 nM) with FK-
506 Binding Protein 12 (FKBP12). This complex then inhibits the activity of the calcium/calmodulin-dependent protein phosphatase, calcineurin, leading to disruption of T cell activation. The physiological effects of FK-506 also include regulation of nitric oxide neurotoxicity, neurotransmitter release, and regulation of Ca
2+ release
via the ryanodine and inositol-
(1,4,5)-
trisphosphate (IP
3) receptors. In the latter case, FKBP12 forms a tight complex with both ryanodine and IP
3 receptors which can be disrupted by FK-506, thereby rendering the receptors “leaky” to Ca
2+.
一般的な説明
This stable-labeled internal standard is suited for quantitation of tacrolimus by LC/MS or GC/MS for clinical toxicology, therapeutic drug monitoring, or isotope dilution methods. Tacrolimus, also known as FK-506 or fujimycin, is an immunosuppressive drug marketed as Prograf, Advagraf, and Protopic usually used to prevent rejection of organ transplants and treatment of eczema. Use of a stable-labeled analog of tacrolimus is the best choice to minimize variability or mitigate any potential interference in LC-MS/MS analysis.
FK-506-13C-d2 上流と下流の製品情報
原材料
準備製品
FK-506-13C-d2 生産企業
Global( 25)Suppliers
- 1356841-89-8
- (3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-Hexadecahydro-5,19-dihydroxy-3-[(1E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl-3-13C-d2)-15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone
- Tacrolimus-13C
- Tacrolimus-13C,D2 solution
- TACROLIMUS (13C, 99%
- FK-506-13C,D2 (Major) (Tacrolimus)
(>
- (3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-Hexadecahydro-5,19-dihydroxy-3-[(1E)-2-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl-3-13C-d2)-
- FK-506-13C,D2 (Major) (Tacrolimus)(>85%)
- D2, 98%) 100 UG/ML IN ACETONITRILE
- Tacrolimus 13CD2Q: What is
Tacrolimus 13CD2 Q: What is the CAS Number of
Tacrolimus 13CD2 Q: What is the storage condition of
Tacrolimus 13CD2 Q: What are the applications of
Tacrolimus 13CD2
- Fujimycin-13C,D2 Tacrolimus-13C D2 FK-506-13C,D2
- Methadone Hydrochloride Impurity 9
- Tacrolimus-13C, D2 (major)